in this issue
EnviroTech :: Biotech
U.S. Firm Acquires Novozymes Biopharma Sweden
10:16 AM MDT | November 3, 2011 | Deepti Ramesh
Biopharmaceutical company Repligen (Waltham, MA) says it has signed a definitive agreement to acquire Novozymes Biopharma Sweden (Lund, Sweden), a business of Novozymes (Bagsvaerd, Denmark), for €17 million ($24 million) and future potential milestone payments of €4 million. The acquisition will help Repligen to become a leading supplier of products for manufacturing biologic drugs. The transaction is expected to be finalized during the fourth quarter of 2011. The combined company is expected to generate total sales of about $50 million in fiscal year...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee